Literature DB >> 11201152

[Development of Hodgkin's disease four years after autologous peripheral blood stem cell transplantation for multiple myeloma].

H Fujii1, T Iwai, Y Ueda, H Nakagawa.   

Abstract

We report a case of Hodgkin's disease that developed 4 years after autologous peripheral blood stem cell transplantation (PBSCT). The patient, a 67-year-old Japanese male, underwent PBSCT for multiple myeloma (IgA-lambda type) under a conditioning regimen of carboplatin, etoposide and cyclophosphamide in June 1994 and obtained partial remission. In January 1995, he underwent a second PBSCT under a conditioning regimen of high-dose melphalan and obtained complete remission. In December 1998, he noticed swelling of the left cervical lymph nodes, and Hodgkin's disease of the mixed cellularity subtype was diagnosed from a lymph node biopsy sample. Immunohistochemistry studies showed that the Hodgkin's and Reed-Sternberg cells were CD30-positive. In situ hybridization using EBER probes showed that these cells expressed EBER RNA transcripts, indicating that the tumor was associated with Epstein-Barr virus. One noteworthy feature was the absence of both M-component in the serum and urine, as revealed by immunoelectrofixation, and plasmacytosis in the bone marrow, which would have indicated relapse of the multiple myeloma. After chemotherapy with MOPP and ABVD, the Hodgkin's disease was eradicated and the patient obtained complete remission in May 1999.

Entities:  

Mesh:

Year:  2000        PMID: 11201152

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  1 in total

1.  Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.

Authors:  Rajendra Gharbaran; Andre Goy; Takemi Tanaka; Jongwhan Park; Chris Kim; Nafis Hasan; Swathi Vemulapalli; Sreeja Sarojini; Madalina Tuluc; Kip Nalley; Pritish Bhattacharyya; Andrew Pecora; K Stephen Suh
Journal:  J Hematol Oncol       Date:  2013-08-29       Impact factor: 17.388

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.